OliX Pharmaceuticals Presents New Data on Asymmetric siRNA Therapy at TIDES: Oligonucleotides …

SUWON, Korea, Sept. 15, 2020 (GLOBE NEWSWIRE) — OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today presented a poster at the TIDES: Oligonucleotides and Peptide Therapeutics 2020 Virtual Conference. The presentation entitled, “Asymmetric siRNA Therapeutics by OliX Pharmaceuticals,” highlights OliX’ proprietary asiRNA platform technology along with the preclinical/clinical development of various programs.

The Company presented the clinical development status of OLX101A, a cell-penetrating asymmetric siRNA (cp-asiRNA) targeting hypertrophic and keloid scars. OliX also presented data on ophthalmic pipelines that demonstrate the efficacy of OLX301A, targeting wet and dry age-related macular degeneration (AMD) in rodents and non-human primate disease models. In addition, OLX301D, targeting subretinal fibrosis and wet AMD, showed efficacy in relevant animal models. The Company also showcased data for its GalNAc-asiRNA platform technology for the treatment of liver diseases.

The presentation can be found on TIDES website https://tidesus2020.eventfinity.co/directories/17271/attendee/284822387.

“This data further validates

Read More

Continue Reading

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) – Return On Capital Employed Overview: Rigel Pharmaceuticals

Rigel Pharmaceuticals (NASDAQ: RIGL) reported Q2 sales of $16.02 million. Earnings fell to a loss of $17.39 million, resulting in a 182.71% decrease from last quarter. In Q1, Rigel Pharmaceuticals earned $21.03 million, and total sales reached $55.76 million.

Why ROCE Is Significant

Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed in a business. Changes in earnings and sales indicate shifts in a company’s ROCE. A higher ROCE is generally representative of successful growth in a company and is a sign of higher earnings per share for shareholders in the future. A low or negative ROCE suggests the opposite. In Q2, Rigel Pharmaceuticals posted an ROCE of -0.28%.

Keep in mind, while ROCE is a good measure of a company’s recent performance, it is not a highly reliable predictor of a company’s earnings or sales in the near future.

ROCE is an important

Read More

Continue Reading

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fennec Pharmaceuticals Inc. (FENC)

LOS ANGELES, Sept. 17, 2020 /PRNewswire/ — Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming November 2, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of Fennec Pharmaceuticals Inc. (“Fennec” or the “Company”) (NASDAQ: FENC) securities between February 11, 2020 and August 10, 2020, inclusive (the “Class Period”).

(PRNewsfoto/Glancy Prongay & Murray LLP)

If you suffered a loss on your Fennec investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/fennec-pharmaceuticals-inc/.You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.

On August 11, 2020, before the market opened, Fennec disclosed that it had received a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) regarding

Read More

Continue Reading

Opioids Market is Booming Worldwide (2020-2026)-Says

Opioids Market is Booming Worldwide (2020-2026)-Says

LOS ANGELES, United States: QY Research has recently published a research report titled, “Global Opioids Market Research Report 2020″. This report has been prepared by experienced and knowledgeable market analysts and researchers. It is a phenomenal compilation of important studies that explore the competitive landscape, segmentation, geographical expansion, and revenue, production, and consumption growth of the global Opioids market. Players can use the accurate market facts and figures and statistical studies provided in the report to understand the current and future growth of the global Opioids market.

The report includes CAGR, market shares, sales, gross margin, value, volume, and other vital market figures that give an exact picture of the growth of the global Opioids market.

Top Companies/Manufacturers:
, Purdue Pharma L.P., West-Ward Pharmaceuticals Corporation, Allergan, Pfizer, Inc., Janssen Pharmaceuticals, Inc., Egalet Corporation, Sun Pharmaceutical Industries Limited.

Market Segment by Product Type: Immediate-Release/Short-Acting Opioid, Extended-Release/Long-Acting Opioid

Market Segment by Application:

Read More

Continue Reading

Cantabio Pharmaceuticals receives grant from Michael J. Fox Foundation to develop a novel DJ-1 protein-based biomarker for Parkinson’s Disease

Grant enables the development of new detection technologies for DJ-1 in biofluids to create a new biomarker for the potential early diagnosis and tracking of the progression of Parkinson’s disease

PALO ALTO, CA / ACCESSWIRE / September 16, 2020 / Cantabio Pharmaceuticals, Inc. (“Cantabio” or the “Company”), a preclinical stage pharmaceutical company developing disease modifying therapeutics for Alzheimer’s (AD), Parkinson’s (PD) and Type II diabetes, today announced that The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded the Company a grant entitled “Development of Assays to Quantify DJ-1 in Distinct Oxidized States of Cys106 as a Potential Biomarker for Parkinson’s Disease”. This grant supports the Company’s ongoing DJ-1 focused biomarker research program aiming at allowing early diagnosis and tracking the progress of PD.

Currently no available clinical biomarkers exist for PD, so this is an area of critical unmet need both in the early detection and treatment of

Read More

Continue Reading

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Shares Bought by Bank of Montreal Can

Bank of Montreal Can grew its holdings in shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) by 256.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 6,686 shares of the biopharmaceutical company’s stock after purchasing an additional 4,808 shares during the period. Bank of Montreal Can’s holdings in Arena Pharmaceuticals were worth $440,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Monashee Investment Management LLC acquired a new stake in shares of Arena Pharmaceuticals during the second quarter worth $6,925,000. Geode Capital Management LLC grew its position in shares of Arena Pharmaceuticals by 6.6% during the first quarter. Geode Capital Management LLC now owns 745,805 shares of the biopharmaceutical company’s stock worth $31,323,000 after acquiring an additional 46,124 shares during the last quarter. Massachusetts Financial Services Co. MA grew its position in

Read More

Continue Reading

Ionis Pharmaceuticals Inc (NASDAQ:IONS) Shares Sold by Mitsubishi UFJ Trust & Banking Corp

Mitsubishi UFJ Trust & Banking Corp lowered its position in shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 0.6% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 464,875 shares of the company’s stock after selling 2,855 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp owned about 0.33% of Ionis Pharmaceuticals worth $27,409,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of IONS. Vanguard Group Inc. increased its stake in shares of Ionis Pharmaceuticals by 2.1% in the second quarter. Vanguard Group Inc. now owns 12,306,251 shares of the company’s stock worth $725,576,000 after acquiring an additional 252,690 shares during the period. Clearbridge Investments LLC grew its position in Ionis Pharmaceuticals by 1.1% during the 1st quarter. Clearbridge Investments LLC now owns 8,034,264 shares of

Read More

Continue Reading

Tonix Pharmaceuticals to Host Live Webinar: Antibody vs. T Cell Immunity: Is a Single Vaccine Enough to Stop COVID-19?

The MarketWatch News Department was not involved in the creation of this content.

NEW YORK, Sep 17, 2020 (GLOBE NEWSWIRE via COMTEX) —
Webinar to be Moderated by Clive Cookson of the Financial Times on September 24, 2020

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it will host a live webinar on Thursday, September 24, 2020 at 10:00 a.m. ET to discuss the concept of two types of immune responses – antibody vs. T Cell – as well as provide an overview of the challenges of developing an effective vaccine.

Participating panelists for the event will be:

— Swati Gupta, Vice President and Head of Emerging Infectious Diseases and Scientific Strategy, IAVI. Click HERE for full bio.

— Seth Lederman, M.D., Co-Founder and CEO, Tonix Pharmaceuticals. Click HERE for full bio.

— Gokul Swaminathan, Associate Principal Scientist, Investigational Biology, Merck

Read More

Continue Reading

Why ARWR Stock Is Shooting 45% Higher Today



a close up of electronics: Image of the Arrowhead Pharmaceuticals (ARWR) website with a magnifying glass focusing on the logo


© Source: Pavel Kapysh / Shutterstock.com
Image of the Arrowhead Pharmaceuticals (ARWR) website with a magnifying glass focusing on the logo

Arrowhead Pharmaceuticals (NASDAQ:ARWR) news for Wednesday includes positive interim results from a clinical trial pushing ARWR stock higher.



a close up of a screen: Image of the Arrowhead Pharmaceuticals (ARWR) website with a magnifying glass focusing on the logo


© Provided by InvestorPlace
Image of the Arrowhead Pharmaceuticals (ARWR) website with a magnifying glass focusing on the logo

According to a recent Arrowhead Pharmaceuticals news release, the company has seen significant results from its AROAAT2002 trial. This is a clinical trial that tests the effectiveness of using ARO-AAT to treat patients suffering from a “rare genetic liver disease associated with alpha-1 antitrypsin deficiency (AATD).”

The interim results of the study show that ARO-AAT has been successful in affecting several biomarkers. This includes intra-hepatic mutant AAT protein (Z-AAT), Z-AAT monomer and Z-AAT polymer, liver stiffness, alanine aminotransferase (ALT) and gamma-glutamyl transferase (GGT).

The Arrowhead Pharmaceuticals news release notes that

Read More

Continue Reading

Looking Into Arrowhead Pharmaceuticals’s Return On Capital Employed

Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported Q3 sales of $27.38 million. Earnings fell to a loss of $15.95 million, resulting in a 28.3% decrease from last quarter. Arrowhead Pharmaceuticals collected $23.53 million in revenue during Q2, but reported earnings showed a $22.24 million loss.

What Is ROCE?

Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed in a business. Changes in earnings and sales indicate shifts in a company’s ROCE. A higher ROCE is generally representative of successful growth in a company and is a sign of higher earnings per share for shareholders in the future. A low or negative ROCE suggests the opposite. In Q3, Arrowhead Pharmaceuticals posted an ROCE of -0.03%.

Keep in mind, while ROCE is a good measure of a company’s recent performance, it is not a highly reliable predictor of a company’s earnings or sales in the near future.

View

Read More

Continue Reading

Load More